Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
Wu YS, Zhang WW, Ling XM, Yang L, Huang SB, Wang XC, Wu H, Cai WP, Wang M, Wang H, Liu YF, He HL, Wei FL, Wu ZY, Zhang FJ. Wu YS, et al. Among authors: he hl. Chin Med J (Engl). 2016 Feb 5;129(3):304-8. doi: 10.4103/0366-6999.174509. Chin Med J (Engl). 2016. PMID: 26831232 Free PMC article.
Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings: A randomised, open-label and non-inferiority study from China.
Li L, He H, Lan Y, Chen J, Zhong H, Nie J, Chen X, Hu F, Tang X, Cai W. Li L, et al. Among authors: he h. Indian J Med Microbiol. 2018 Oct-Dec;36(4):513-516. doi: 10.4103/ijmm.IJMM_18_172. Indian J Med Microbiol. 2018. PMID: 30880698 Free article. Clinical Trial.
Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China.
Guo PL, He HL, Chen XJ, Chen JF, Chen XT, Lan Y, Wang J, Du PS, Zhong HL, Li H, Liu C, Li LY, Hu FY, Tang XP, Cai WP, Li LH. Guo PL, et al. Among authors: he hl. Front Pharmacol. 2021 Mar 25;11:569766. doi: 10.3389/fphar.2020.569766. eCollection 2020. Front Pharmacol. 2021. PMID: 33841131 Free PMC article.
16,385 results
You have reached the last available page of results. Please see the User Guide for more information.